 This study is a single arm, multi-center phase II study of olaparib monotherapy in patients with relapsed small cell lung cancer SCLC harboring HR pathway gene mutations not limited to BRCA 12 mutations, ATM deficiency or MRE11A mutations as second or third line chemotherapy. 